Место локальной терапии в лечении остеоартроза
Шостак Н.А., Клименко А.А. Место локальной терапии в лечении остеоартроза. Consilium Medicum. 2008; 10 (7): 141–145.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Рациональная фармакотерапия ревматических заболеваний. Рук-во для практикующих врачей. Под ред. В.А.Насоновой, Е.Л.Насонова. М.: Литтера, 2003.
2. Шостак Н.А. Остеоартроз – современные подходы к диагностике и лечению. Рус. мед. журн. 2003; 11 (14): 803–7.
3. Павлова В.Н., Копьева Т.Н., Слуцкий Л.И. и др. Хрящ. М.: Медицина, 1988.
4. Кellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957; 16 (4): 494–502.
5. National Institute for Health and Clinical Excellence. Osteoarthritis. The care and management of osteoarthritis in adults. NICE clinical guideline 59, 2008.
6. Ding C. Do NSAID affect the progression of osteoarthritis? Inflammation 2002; 26: 139–42.
7. Menasse R, Hedwall PR, Kraetz J et al. Pharmacological properties of didofenac sodium and its metabolites. Scand J Rheumatol 1978, Suppl. 22: 5–16.
8. Zhang W, Doherty M. EULAR recommendations for knee and hip osteoarthritis: a critique of the methodology.Br J Sports Med 2006; 40 (8): 664–9.
9. Zhang W, Doherty M, Leeb BF et al. EULAR evidence based recommendations for themanagement of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66; 377–88.
10. Jordan KM, Arden NK, Doherty M et al. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62 (12): 1145–55.
11. Sintov AC, Botner S. Transdermal drug delivery using microemulsion and aqueous systems: influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems. Int J Pharm 2006; 311 (1–2): 55–62.
12. Riess W, Schmid K, Botta L et al. The percutaneous absorption of diclofenac. Arzneimittelforschung 1986; 36 (7): 1092–6.
13. Grace D, Rogers J, Skeith K, Anderson K. Topical diclofenac versus placebo: a double blind, randomised clinical trial in patients with osteoarthritis of the knee. J Rheumatol 1999; 26: 2659–63.
14. Dreiser RL, Tisne-Camus M. DHEP plasters as a topical treatment of knee osteoarthritis – a double blind placebo-controlled study. Drugs Exp Clin Res 1993; 19: 121–7.
15. Ottilinger B, Gomor B, Michel BA et al. Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 2001; 9: 273–80.
16. Parsaee S, Sarbolouki MN, Parnianpour M. In-vitro release of diclofenac diethylammonium from lipid-based formulations. Int J Pharm 2002; 241 (1): 185–90.
17. Rosim GC, Barbieri CH, Lan_as FM, Mazzer N. Diclofenac phonophoresis in human volunteers. Ultrasound Med Biol 2005; 31 (3): 337–43.
2. Шостак Н.А. Остеоартроз – современные подходы к диагностике и лечению. Рус. мед. журн. 2003; 11 (14): 803–7.
3. Павлова В.Н., Копьева Т.Н., Слуцкий Л.И. и др. Хрящ. М.: Медицина, 1988.
4. Кellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957; 16 (4): 494–502.
5. National Institute for Health and Clinical Excellence. Osteoarthritis. The care and management of osteoarthritis in adults. NICE clinical guideline 59, 2008.
6. Ding C. Do NSAID affect the progression of osteoarthritis? Inflammation 2002; 26: 139–42.
7. Menasse R, Hedwall PR, Kraetz J et al. Pharmacological properties of didofenac sodium and its metabolites. Scand J Rheumatol 1978, Suppl. 22: 5–16.
8. Zhang W, Doherty M. EULAR recommendations for knee and hip osteoarthritis: a critique of the methodology.Br J Sports Med 2006; 40 (8): 664–9.
9. Zhang W, Doherty M, Leeb BF et al. EULAR evidence based recommendations for themanagement of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66; 377–88.
10. Jordan KM, Arden NK, Doherty M et al. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62 (12): 1145–55.
11. Sintov AC, Botner S. Transdermal drug delivery using microemulsion and aqueous systems: influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems. Int J Pharm 2006; 311 (1–2): 55–62.
12. Riess W, Schmid K, Botta L et al. The percutaneous absorption of diclofenac. Arzneimittelforschung 1986; 36 (7): 1092–6.
13. Grace D, Rogers J, Skeith K, Anderson K. Topical diclofenac versus placebo: a double blind, randomised clinical trial in patients with osteoarthritis of the knee. J Rheumatol 1999; 26: 2659–63.
14. Dreiser RL, Tisne-Camus M. DHEP plasters as a topical treatment of knee osteoarthritis – a double blind placebo-controlled study. Drugs Exp Clin Res 1993; 19: 121–7.
15. Ottilinger B, Gomor B, Michel BA et al. Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 2001; 9: 273–80.
16. Parsaee S, Sarbolouki MN, Parnianpour M. In-vitro release of diclofenac diethylammonium from lipid-based formulations. Int J Pharm 2002; 241 (1): 185–90.
17. Rosim GC, Barbieri CH, Lan_as FM, Mazzer N. Diclofenac phonophoresis in human volunteers. Ultrasound Med Biol 2005; 31 (3): 337–43.
Авторы
Н.А.Шостак, А.А.Клименко
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.